KROS (kerostx.com) Earnings per share growth this year

Official company branding of Keros Corp (KROS)

Keros Therapeutics (KROS) maintains an impeccable reputation within the scientific community, developing promising treatments for blood and lung pathologies. The success of elrumiset and trozaluset clinical trials creates a foundation for a potential acquisition of the company. Year-over-year EPS growth confirms this momentum, where the value of -257.50 reflects this status. Research into tissue regulation and the drug luspatercept allow the brand to contend for leadership within the niche.

KROS (kerostx.com) Earnings per share growth in current year history from 07/04/2022 to 11/18/2026

Financial and market metric breakdowns for kerostx.com (KROS)

- stock value and consensus price forecast:
Basic company analysis:Keros Corp (KROS)
Manufactured products of Keros Therapeutics

For Keros Therapeutics (KROS), profit dynamics depend critically on the cost efficiency of late-stage clinical trials for hematological drugs. A comparative analysis of EPS against the same period last year measures the annual growth rate of net income per share, allowing investors to assess the business model's resilience to shocks and determine the company's long-term capitalization trajectory.

Main competitors

Earnings per share growth rate in current year Vertex Pharmaceuticals Inc. (VRTX)|ALNY (Alnylam) - Earnings growth in current year|Earnings per share growth this year INSM (Insmed)|Net earnings per share growth this year UTHR (United Therapeutics Corporation)|BMRN (BioMarin Pharmaceutical Inc.) - Earnings per share increase in current year|Earnings per share growth in current year BridgeBio BBIO|Earnings per share increase in current year BGM|Cogent Biosciences - Earnings growth in current year|Earnings per share increase in current year XERS (Xeris Biopharma)|ARCT: Earnings growth in current year|Eton Pharmaceuticals Inc (ETON) - Earnings growth in current year|Earnings per share growth in current year Kamada Corp|FULC: Earnings per share increase in current year|Earnings per share growth in current year Abeona Therapeutics, Inc. (ABEO)|Net earnings per share growth this year Mereo BioPharma Group plc MREO|Earnings per share growth in current year Protalix BioTherapeutics PLX|Earnings growth in current year Pliant Therapeutics PLRX|appliedtherapeutics.com - Earnings growth in current year|Earnings per share increase in current year RNTX (Rein Therapeutics, Inc.)|GELS: Earnings growth in current year|Earnings per share growth rate in current year Aytu BioPharma, Inc. (AYTU)|CMMB (Chemomab Therapeutics Ltd) - Earnings growth in current year|Earnings per share growth this year SRXH (SRx Health Solutions)|Net earnings per share growth this year PLRZ (Polyrizon Ltd)|AEZS - Earnings per share growth rate in current year|Earnings per share growth in current year Cyclo Therapeutics Inc. CYTH|Inozyme Pharma, Inc. (INZY) - Earnings per share growth rate in current year|RPHM: Net earnings per share growth this year|Earnings per share growth rate in current year COSCIENS Biopharma Inc